Author | Radiation (within the previous 3 months) | Antibiotics (within the previous 2 months) | Age (years) (<65 vs. ≥65) |
PD-L1 (1%–49%) |
PD-L1 (>50%) |
Anti-PD(L)1 compound—nivolumab | Anti-PD(L)1 compound—pembrolizumab | Anti-PD(L)1 compound—atezolizumab | |
---|---|---|---|---|---|---|---|---|---|
Umang Swami (11) | 2.35 [1.36, 4.06] p < 0.01 |
1.73 [1.00, 2.99] p = 0.05 |
1.11 [0.95, 1.29] p = 0.19 |
NA | NA | NA | NA | NA | |
A. Cortellini (12) | NA | 1.42 [0.91, 2.22] p = 0.1207 |
NA | 0.93 [0.61, 1.43] p = 0.7731 |
0.59 [0.37, 0.94] p = 0.0282 |
NA | NA | NA | |
Anne Schett (14) | 1.60 [0.56, 4.51] p = 0.38 |
3.71 [1.34, 10.4] p = 0.01 |
0.98 [0.51, 1.90] p = 0.96 |
7.08 [2.60, 19.3] p < 0.01 |
3.29 [1.13, 9.58] p = 0.03 |
4.29 [2.48, 7.39] p < 0.01 |
2.12 [0.88, 5.08] p = 0.09 |
1.09 [0.14, 18.47] p = 0.93 |
|
Chirayu Mohindroo (15) | NA | 0.99 [0.76, 1.28] p = 0.93 |
0.94 [0.73, 1.21] p = 0.64 |
NA | NA | NA | NA | NA | |
L. Derosa-1 (17) | NA | 2.4 [1.1, 5.7] p = 0.04 |
0.8 [0.4, 1.5] p = 0.43 | NA | NA | NA | NA | NA | |
L. Derosa-2 (17) | NA | 2.9 [1.9, 4.4] p < 0.01 |
1.3 [0.9, 1.9] p = 0.23 |
NA | NA | NA | NA | NA | |
NADINA TINSLEY (18) | NA | 1.699 p = 0.002 |
1.012 p = 0.076 |
NA | NA | NA | NA | NA | |
Hyunho Kim (19) | NA | 2.476 [1.568, 3.911] p < 0.001 |
NA | 1.839 [0.67, 4.99] p = 0.233 |
1.329 [0.52, 3.43] p = 0.557 |
1.001, p = 0.363 | 1.31 [0.79, 2.173] p = 0.295 |
0.801 [0.410, 1.564] p = 0.516 |
F, female; M, male; HR, hazard ratio; NA, not available; ECOG PS, Eastern Cooperative Oncology Group performance status.